Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefania Cheli

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Pharmacology|August 18, 2015
ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease InhibitorsAndrea Lombardi, Simona Landonio, Carlo Magni, et al.
Journal of Pharmacy Practice|September 6, 2025
Olmesartan-Induced Enteropathy: Case Reports and Insights From FDA Adverse Event Reporting System (FAERS)Ilaria Mariani, Giulia Mosini, Stefania Cheli, et al.
The Pharmacogenomics Journal|April 14, 2021
ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairmentStefania Cheli, Sara Baldelli, Annalisa De Silvestri, et al.
Clinical and Experimental Pharmacology & Physiology|November 4, 2016
Renal function in HIV/HBV co-infected and HBV mono-infected patients on a long-term treatment with tenofovir in real life settingLaura Milazzo, Cristina Gervasoni, Felicia Stefania Falvella, et al.
Drug Metabolism and Personalized Therapy|June 11, 2017
Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictorsFelicia Stefania Falvella, Elena Ricci, Stefania Cheli, et al.
Drug Metabolism and Personalized Therapy|July 31, 2016
Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen?Felicia Stefania Falvella, Susan Marelli, Stefania Cheli, et al.
Pharmacological Research|July 27, 2021
The use of biological agents in pregnant women affected by autoimmune disorders: Why we need more research of this neglected areaCarla Carnovale, Francesca Parisi, Vera Battini, et al.
The Pharmacogenomics Journal|May 25, 2023
Correction to: One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective studyStefania Cheli, Diego Savino, Annalisa De Silvestri, et al.
The Pharmacogenomics Journal|April 4, 2023
One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective studyStefania Cheli, Diego Savino, Annalisa De Silvestri, et al.
Therapeutic Drug Monitoring|January 4, 2017
Pharmacokinetics and Pharmacogenetics of Selective Serotonin Reuptake Inhibitors During Pregnancy: An Observational StudyLaura Pogliani, Felicia S Falvella, Dario Cattaneo, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Pharmacology|August 18, 2015
ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease InhibitorsAndrea Lombardi, Simona Landonio, Carlo Magni, et al.
Journal of Pharmacy Practice|September 6, 2025
Olmesartan-Induced Enteropathy: Case Reports and Insights From FDA Adverse Event Reporting System (FAERS)Ilaria Mariani, Giulia Mosini, Stefania Cheli, et al.
The Pharmacogenomics Journal|April 14, 2021
ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairmentStefania Cheli, Sara Baldelli, Annalisa De Silvestri, et al.
Clinical and Experimental Pharmacology & Physiology|November 4, 2016
Renal function in HIV/HBV co-infected and HBV mono-infected patients on a long-term treatment with tenofovir in real life settingLaura Milazzo, Cristina Gervasoni, Felicia Stefania Falvella, et al.
Drug Metabolism and Personalized Therapy|June 11, 2017
Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictorsFelicia Stefania Falvella, Elena Ricci, Stefania Cheli, et al.
Drug Metabolism and Personalized Therapy|July 31, 2016
Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen?Felicia Stefania Falvella, Susan Marelli, Stefania Cheli, et al.
Pharmacological Research|July 27, 2021
The use of biological agents in pregnant women affected by autoimmune disorders: Why we need more research of this neglected areaCarla Carnovale, Francesca Parisi, Vera Battini, et al.
The Pharmacogenomics Journal|May 25, 2023
Correction to: One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective studyStefania Cheli, Diego Savino, Annalisa De Silvestri, et al.
The Pharmacogenomics Journal|April 4, 2023
One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective studyStefania Cheli, Diego Savino, Annalisa De Silvestri, et al.
Therapeutic Drug Monitoring|January 4, 2017
Pharmacokinetics and Pharmacogenetics of Selective Serotonin Reuptake Inhibitors During Pregnancy: An Observational StudyLaura Pogliani, Felicia S Falvella, Dario Cattaneo, et al.
Pageof 5